Introduction

- Depression is common health issue in Germany, with an overall prevalence of 8.1 patients per 100 persons (1).
- The most commonly prescribed pharmaceutical treatment prescribed in Europe are the selective serotonin (norepinephrine) reuptake inhibitors (SS(n)RI) (2, 3).
- The German health system accepts treatment of depression by both general practitioners (GP) and Neurologists/psychiatrists (NP) (4).
- It unknown how much GPs are involved in the treatment of depression in Germany and if patients receive treatment from both specialties.

Objectives

- The aim of the study was to investigate the prescription (Rx) patterns of Selective Serotonin (Norepinephrine) Reuptake Inhibitors (SS(N)RI) in patients treated by GPs and NPs.

Methods

Data source

- The IMS® LRx database served to identify eligible patients (5).
- Contains around 60% of prescriptions reimbursed by statutory health insurance funds.
- Reflects the actual dispensation of drugs.
- Full product information and prescription information are available.

Study population

<table>
<thead>
<tr>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
</table>
✓ initial Rx of ss(n)RI in 2016 prescribed by a GP or a NP | Age at index below 18 years                     |
✓ At least 12 months of pre-index data          | Initial treatment with Milnacipram             |
✓ 12 months of follow-up data available         |                                               |

Statistical analyses

- The primary outcome was the proportion of patients that received Rx from both a GP and a NP.
- Cox regression model evaluating age, gender, substance, type of physician and previous prescription of other antidepressants.
- Kaplan-Meier plots were created to visualize the associations.

Results

- The majority of patients received the first Rx from a GP (58.6%). There were slight differences in the baseline characteristics of the two patient cohorts (table1).
- Over one third of patients (36.1%) of patients initially treated by a GP and 30% of patients initially treated by a NP, received only 1 Rx.
- Of the patients who received at least two prescriptions, 26.3% switched prescriber during follow-up (24.5% of patients initially treated by a GP and 28.4% of patients initially treated by a NP).
- Switching prescriber was more likely if a patient received the initial prescription by a NP, if patients are younger at index and for those who received previous prescriptions for AD. The likelihood was also higher for patients starting on Sertraline and Venlafaxine.

Conclusions

- The majority of the patients (60%) received their initial ss(n)RI from a GP indicating that the GP plays an important role in the treatment of depression in Germany.
- Future studies should therefore also focus on the role of GPs in the treatment of depression.